These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 32740999)

  • 1. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration.
    Landa J; Gaig C; Plagumà J; Saiz A; Antonell A; Sanchez-Valle R; Dalmau J; Graus F; Sabater L
    Ann Neurol; 2020 Nov; 88(5):1023-1027. PubMed ID: 32740999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome.
    Sabater L; Planagumà J; Dalmau J; Graus F
    J Neuroinflammation; 2016 Sep; 13(1):226. PubMed ID: 27586161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons.
    Ryding M; Gamre M; Nissen MS; Nilsson AC; Okarmus J; Poulsen AAE; Meyer M; Blaabjerg M
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic-Bulbar MRI Hyperintensity in Anti-IgLON5 Disease with Serum-Restricted Antibodies: A Case Report and Systematic Review of Literature.
    Tagliapietra M; Frasson E; Cardellini D; Mariotto S; Ferrari S; Zanusso G; Plebani M; Monaco S
    J Alzheimers Dis; 2021; 79(2):683-691. PubMed ID: 33337376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients' IgLON5 autoantibodies interfere with IgLON5-protein interactions.
    Landa J; Serafim AB; Gaig C; Saiz A; Koneczny I; Hoftberger R; Santamaria J; Dalmau J; Graus F; Sabater L
    Front Immunol; 2023; 14():1151574. PubMed ID: 37033996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice.
    Ni Y; Feng Y; Shen D; Chen M; Zhu X; Zhou Q; Gao Y; Liu J; Zhang Q; Shen Y; Peng L; Zeng Z; Yin D; Hu J; Chen S
    J Neuroinflammation; 2022 Jun; 19(1):140. PubMed ID: 35690819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease.
    Gaig C; Compta Y
    Curr Opin Neurol; 2019 Jun; 32(3):493-499. PubMed ID: 30694925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-IgLON5 syndrome - what is our current understanding?].
    Wenninger S; Schoser B
    Fortschr Neurol Psychiatr; 2018 Sep; 86(9):559-565. PubMed ID: 30257262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglial and Neuronal TDP-43 Pathology in Anti-IgLON5-Related Tauopathy.
    Cagnin A; Mariotto S; Fiorini M; Gaule M; Bonetto N; Tagliapietra M; Buratti E; Zanusso G; Ferrari S; Monaco S
    J Alzheimers Dis; 2017; 59(1):13-20. PubMed ID: 28550263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgLON5 autoimmunity tested positive in patients with isolated chronic insomnia disease.
    Aghelan Z; Karima S; Ghadami MR; Khazaie H; Bahrehmand F; Vaisi-Raygani A; Abtahi SH; Khodarahmi R
    Clin Exp Immunol; 2022 Apr; 207(2):237-240. PubMed ID: 35020856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.
    Gaig C; Ercilla G; Daura X; Ezquerra M; Fernández-Santiago R; Palou E; Sabater L; Höftberger R; Heidbreder A; Högl B; Iranzo A; Santamaria J; Dalmau J; Graus F
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical manifestations of the anti-IgLON5 disease.
    Gaig C; Graus F; Compta Y; Högl B; Bataller L; Brüggemann N; Giordana C; Heidbreder A; Kotschet K; Lewerenz J; Macher S; Martí MJ; Montojo T; Pérez-Pérez J; Puertas I; Seitz C; Simabukuro M; Téllez N; Wandinger KP; Iranzo A; Ercilla G; Sabater L; Santamaría J; Dalmau J
    Neurology; 2017 May; 88(18):1736-1743. PubMed ID: 28381508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease.
    Morales-Briceño H; Cruse B; Fois AF; Lin MW; Jiang J; Banerjee D; Grunstein R; Varikatt W; Rodriguez M; Shepherd C; Fung VSC
    Neurology; 2018 Jun; 90(24):1113-1115. PubMed ID: 29769372
    [No Abstract]   [Full Text] [Related]  

  • 14. Teaching Video NeuroImages: Anti-IgLON5 Disease: A Long-Course Presentation With a Response to Immunotherapy.
    Villacieros-Álvarez J; Ordás CM; Torres-Gaona G; Díez-Barrio A; Prieto-Jurczynska C; Gaig C
    Neurology; 2021 Jun; 96(23):e2901-e2902. PubMed ID: 33361260
    [No Abstract]   [Full Text] [Related]  

  • 15. Pilot Study of the Effects of Chronic Intracerebroventricular Infusion of Human Anti-IgLON5 Disease Antibodies in Mice.
    Alvente S; Matteoli G; Molina-Porcel L; Landa J; Alba M; Bastianini S; Berteotti C; Graus F; Lo Martire V; Sabater L; Zoccoli G; Silvani A
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropathological criteria of anti-IgLON5-related tauopathy.
    Gelpi E; Höftberger R; Graus F; Ling H; Holton JL; Dawson T; Popovic M; Pretnar-Oblak J; Högl B; Schmutzhard E; Poewe W; Ricken G; Santamaria J; Dalmau J; Budka H; Revesz T; Kovacs GG
    Acta Neuropathol; 2016 Oct; 132(4):531-43. PubMed ID: 27358064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor-neuron-disease-like phenotype associated with IgLON5 disease.
    Sista SR; Crum B; Aboseif A; Devine MF; Zekeridou A; Hammami MB; Rezk MM; Truffert A; Lalive PH; Kunchok A; McKeon A; Dubey D
    J Neurol; 2022 Nov; 269(11):6139-6144. PubMed ID: 35857139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-neurofilament antibodies and neurodegeneration: Markers and generators.
    Zmira O; Halpern AI; Drori T
    J Neuroimmunol; 2020 Jul; 344():577248. PubMed ID: 32344161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy.
    Erro ME; Sabater L; Martínez L; Herrera M; Ostolaza A; García de Gurtubay I; Tuñón T; Graus F; Gelpi E
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease.
    Grüter T; Möllers FE; Tietz A; Dargvainiene J; Melzer N; Heidbreder A; Strippel C; Kraft A; Höftberger R; Schöberl F; Thaler FS; Wickel J; Chung HY; Seifert F; Tschernatsch M; Nagel M; Lewerenz J; Jarius S; Wildemann BC; de Azevedo L; Heidenreich F; Heusgen R; Hofstadt-van Oy U; Linsa A; Maaß JJ; Menge T; Ringelstein M; Pedrosa DJ; Schill J; Seifert-Held T; Seitz C; Tonner S; Urbanek C; Zittel S; Markewitz R; Korporal-Kuhnke M; Schmitter T; Finke C; Brüggemann N; Bien CI; Kleiter I; Gold R; Wandinger KP; Kuhlenbäumer G; Leypoldt F; Ayzenberg I;
    Brain; 2023 Feb; 146(2):600-611. PubMed ID: 35259208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.